JP2008531536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531536A5 JP2008531536A5 JP2007556662A JP2007556662A JP2008531536A5 JP 2008531536 A5 JP2008531536 A5 JP 2008531536A5 JP 2007556662 A JP2007556662 A JP 2007556662A JP 2007556662 A JP2007556662 A JP 2007556662A JP 2008531536 A5 JP2008531536 A5 JP 2008531536A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- chloro
- acceptable salt
- methoxyquinazolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 26
- 150000003246 quinazolines Chemical class 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- -1 3-chloro-2-fluoroanilino, 3-chloro-4-fluoroanilino Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 125000000524 functional group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- KZPCCHWWIXHAPW-FZKQIMNGSA-N (2r,4r)-4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n,1-dimethylpiperidine-2-carboxamide Chemical compound C1CN(C)[C@@H](C(=O)NC)C[C@@H]1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F KZPCCHWWIXHAPW-FZKQIMNGSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- HGKSSYGJWQWSLQ-SJKOYZFVSA-N (2r,4r)-4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-1-methylpiperidine-2-carboxamide Chemical compound C=12C=C(O[C@H]3C[C@@H](N(C)CC3)C(N)=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F HGKSSYGJWQWSLQ-SJKOYZFVSA-N 0.000 claims 1
- ZFIWABPVEBYZAM-SJKOYZFVSA-N (2r,4r)-4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n-methylpiperidine-2-carboxamide Chemical compound C1CN[C@@H](C(=O)NC)C[C@@H]1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F ZFIWABPVEBYZAM-SJKOYZFVSA-N 0.000 claims 1
- KZPCCHWWIXHAPW-SCLBCKFNSA-N (2r,4s)-4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n,1-dimethylpiperidine-2-carboxamide Chemical compound C1CN(C)[C@@H](C(=O)NC)C[C@H]1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F KZPCCHWWIXHAPW-SCLBCKFNSA-N 0.000 claims 1
- KZPCCHWWIXHAPW-ACJLOTCBSA-N (2s,4r)-4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n,1-dimethylpiperidine-2-carboxamide Chemical compound C1CN(C)[C@H](C(=O)NC)C[C@@H]1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F KZPCCHWWIXHAPW-ACJLOTCBSA-N 0.000 claims 1
- HGKSSYGJWQWSLQ-SJCJKPOMSA-N (2s,4s)-4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-1-methylpiperidine-2-carboxamide Chemical compound C=12C=C(O[C@@H]3C[C@H](N(C)CC3)C(N)=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F HGKSSYGJWQWSLQ-SJCJKPOMSA-N 0.000 claims 1
- KZPCCHWWIXHAPW-UGSOOPFHSA-N (2s,4s)-4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n,1-dimethylpiperidine-2-carboxamide Chemical compound C1CN(C)[C@H](C(=O)NC)C[C@H]1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F KZPCCHWWIXHAPW-UGSOOPFHSA-N 0.000 claims 1
- CIOPUONYTJYZKQ-UHFFFAOYSA-N 1,2-dimethylpiperidine-2-carboxamide Chemical compound CN1CCCCC1(C)C(N)=O CIOPUONYTJYZKQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- KZPCCHWWIXHAPW-UHFFFAOYSA-N 4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n,1-dimethylpiperidine-2-carboxamide Chemical compound C1CN(C)C(C(=O)NC)CC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F KZPCCHWWIXHAPW-UHFFFAOYSA-N 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0504018A GB0504018D0 (en) | 2005-02-26 | 2005-02-26 | Quinazoline derivatives |
| GB0504018.3 | 2005-02-26 | ||
| GB0506657A GB0506657D0 (en) | 2005-03-31 | 2005-03-31 | Quinazoline derivatives |
| GB0506657.6 | 2005-03-31 | ||
| GB0524001.5 | 2005-11-25 | ||
| GB0524001A GB0524001D0 (en) | 2005-11-25 | 2005-11-25 | Quinazoline derivatives |
| PCT/GB2006/000656 WO2006090163A1 (en) | 2005-02-26 | 2006-02-24 | Quinazoline derivatives as tyrosine kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008531536A JP2008531536A (ja) | 2008-08-14 |
| JP2008531536A5 true JP2008531536A5 (https=) | 2009-04-09 |
| JP5054544B2 JP5054544B2 (ja) | 2012-10-24 |
Family
ID=36390222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007556662A Expired - Fee Related JP5054544B2 (ja) | 2005-02-26 | 2006-02-24 | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8735410B2 (https=) |
| EP (1) | EP1856095B1 (https=) |
| JP (1) | JP5054544B2 (https=) |
| KR (1) | KR20070107151A (https=) |
| AR (1) | AR055564A1 (https=) |
| AT (1) | ATE521603T1 (https=) |
| AU (1) | AU2006217738A1 (https=) |
| BR (1) | BRPI0607432A2 (https=) |
| CA (1) | CA2599210A1 (https=) |
| IL (1) | IL184798A0 (https=) |
| MX (1) | MX2007010399A (https=) |
| NO (1) | NO20073878L (https=) |
| TW (1) | TW200640904A (https=) |
| UY (1) | UY29398A1 (https=) |
| WO (1) | WO2006090163A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE395346T1 (de) | 2003-09-16 | 2008-05-15 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| DE602005010824D1 (de) | 2004-02-03 | 2008-12-18 | Astrazeneca Ab | Chinazolinderivate |
| US8629153B2 (en) | 2008-09-03 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Use of quinazoline derivatives for the treatment of viral diseases |
| KR20140096571A (ko) * | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
| CN103288759B (zh) * | 2013-05-16 | 2015-05-20 | 苏州明锐医药科技有限公司 | 达克米替尼的制备方法 |
| CA2974442A1 (en) * | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Novel fluorinated derivatives as egfr inhibitors useful for treating cancers |
| ES2932805T3 (es) * | 2017-09-28 | 2023-01-26 | Chongqing Pharmaceutical Industrial Res Institute Co Ltd | Derivado de quinolina y aplicación del mismo como inhibidor de la tirosina quinasa |
| BR112021004527A2 (pt) * | 2018-09-14 | 2021-06-08 | Spectrum Pharmaceuticals, Inc. | kits e métodos para tratamento contra câncer |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985749A (en) * | 1975-12-22 | 1976-10-12 | Eastman Kodak Company | Process for preparation of 4-aminoquinazoline |
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| US4332420A (en) | 1980-01-11 | 1982-06-01 | Coski William D | Reciprocably supported dual drive member and features thereof |
| GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
| KR910006138B1 (ko) | 1986-09-30 | 1991-08-16 | 에자이 가부시끼가이샤 | 환상아민 유도체 |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
| CA1340821C (en) * | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| US5252586A (en) * | 1990-09-28 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents |
| DE4105503A1 (de) | 1991-02-19 | 1992-08-20 | Jenapharm Gmbh | Ausgangsverbindungen zur herstellung von calcitriol sowie dessen abkoemmlingen, verfahren zur herstellung dieser ausgangsverbindungen sowie zwischenprodukte fuer dieses verfahren |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| US5187168A (en) | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
| GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| WO1993017682A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| AU680004B2 (en) | 1993-05-26 | 1997-07-17 | Syntex (U.S.A.) Inc. | Novel 1-phenylalkanone 5-HT4 receptor ligands |
| US5395846A (en) | 1993-06-25 | 1995-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (https=) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508535D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| JPH11507329A (ja) | 1995-04-27 | 1999-06-29 | ゼネカ リミテッド | キナゾリン誘導体 |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2216169C (en) * | 1996-01-31 | 2007-01-23 | Gist-Brocades B.V. | Use of compositions comprising stabilized biologically effective compounds |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6225318B1 (en) * | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
| JP4245682B2 (ja) | 1997-12-25 | 2009-03-25 | 協和発酵キリン株式会社 | キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤 |
| US6384223B1 (en) * | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| CA2361174C (en) * | 1999-02-27 | 2009-10-27 | Boehringer Ingelheim Pharma Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| AU4145200A (en) | 1999-05-07 | 2000-11-21 | Takeda Chemical Industries Ltd. | Cyclic compounds and uses thereof |
| US6126917A (en) * | 1999-06-01 | 2000-10-03 | Hadasit Medical Research Services And Development Ltd. | Epidermal growth factor receptor binding compounds for positron emission tomography |
| HK1044769B (zh) * | 1999-06-21 | 2005-02-25 | 贝林格尔英格海姆法玛两合公司 | 雙環雜環化合物，含有該化合物的藥物組合物，該化合物的用途及其製備方法 |
| CA2407088A1 (en) | 2000-05-19 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Beta-secretase inhibitors |
| DE10042060A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10042062A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung |
| US6653305B2 (en) * | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| DE10042061A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6656946B2 (en) * | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6617329B2 (en) * | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| DE10042059A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10042058A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6740651B2 (en) * | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US20030158196A1 (en) * | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
| US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
| CA2442742A1 (en) | 2001-02-21 | 2002-08-29 | Mitsubishi Pharma Corporation | Quinazoline derivatives |
| US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| EP1396488A1 (en) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| JP4776882B2 (ja) * | 2002-03-30 | 2011-09-21 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 二環式複素環化合物、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法 |
| US20040044014A1 (en) * | 2002-04-19 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| DE10334226A1 (de) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| UY28441A1 (es) * | 2003-07-29 | 2005-02-28 | Astrazeneca Ab | Derivados de quinazolina |
| GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| ES2279441T3 (es) * | 2003-09-19 | 2007-08-16 | Astrazeneca Ab | Derivados de quinazolina. |
| CN1882570B (zh) * | 2003-09-19 | 2010-12-08 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
| WO2005030757A1 (en) * | 2003-09-25 | 2005-04-07 | Astrazeneca Ab | Quinazoline derivatives |
-
2006
- 2006-02-24 KR KR1020077021853A patent/KR20070107151A/ko not_active Withdrawn
- 2006-02-24 TW TW095106212A patent/TW200640904A/zh unknown
- 2006-02-24 JP JP2007556662A patent/JP5054544B2/ja not_active Expired - Fee Related
- 2006-02-24 UY UY29398A patent/UY29398A1/es unknown
- 2006-02-24 CA CA002599210A patent/CA2599210A1/en not_active Abandoned
- 2006-02-24 AU AU2006217738A patent/AU2006217738A1/en not_active Abandoned
- 2006-02-24 AR ARP060100689A patent/AR055564A1/es unknown
- 2006-02-24 US US11/884,923 patent/US8735410B2/en not_active Expired - Fee Related
- 2006-02-24 AT AT06709888T patent/ATE521603T1/de not_active IP Right Cessation
- 2006-02-24 MX MX2007010399A patent/MX2007010399A/es not_active Application Discontinuation
- 2006-02-24 BR BRPI0607432-4A patent/BRPI0607432A2/pt not_active IP Right Cessation
- 2006-02-24 WO PCT/GB2006/000656 patent/WO2006090163A1/en not_active Ceased
- 2006-02-24 EP EP06709888A patent/EP1856095B1/en not_active Expired - Lifetime
-
2007
- 2007-07-23 IL IL184798A patent/IL184798A0/en unknown
- 2007-07-24 NO NO20073878A patent/NO20073878L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002320822B2 (en) | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride | |
| JP2007500177A5 (https=) | ||
| JP5036002B2 (ja) | ２−アミノ−７，８−ジヒドロ−６Ｈ−ピリド［４，３−ｄ］ピリミジン−５−オン | |
| JP2006514626A5 (https=) | ||
| AU2002320822A1 (en) | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride | |
| ES2614612T3 (es) | Derivados de quinazolinona útiles como antagonistas de vanilloides | |
| KR20150016352A (ko) | Ｎ-[5-(3,5-디플루오로-벤질)-1ｈ-인다졸-3-일]-4-(4-메틸-피페라진-1-일)-2-(테트라하이드로-피란-4-일아미노)-벤즈아미드의 제조 방법 | |
| CZ20024223A3 (cs) | Deriváty 4-chinazolinaminů, způsob výroby a farmaceutický prostředek | |
| KR102142797B1 (ko) | 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도 | |
| WO2007082434A1 (en) | Quinazoline derivatives,preparation methods and uses thereof | |
| JP2014524476A5 (https=) | ||
| JP2008531536A5 (https=) | ||
| CA3102296C (en) | Tartrate and crystal form thereof as selective cdk9 inhibitors | |
| JP2009143920A (ja) | 化学的方法 | |
| TWI443095B (zh) | 新穎鹽 | |
| JP2007532658A (ja) | がんの治療方法 | |
| KR20210003807A (ko) | Egfr 3중 돌연변이 억제제로서의 퀴나졸린 화합물 및 이의 응용 | |
| JP2012524769A (ja) | ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンの製造方法 | |
| Abdel Hamid et al. | Substituted Quinazolines, 1. Synthesis and antitumor activity of certain substituted 2-mercapto-4 (3H)-quinazolinone analogs | |
| WO2008033513A1 (en) | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS | |
| EP2199291A1 (en) | Process for preparation of pimobendan hydrochloride | |
| JP2010514685A (ja) | アリール置換ピラゾールアミド化合物の結晶形 | |
| EP2465853A1 (en) | Polymorph of rufinamide and process for obtaining it | |
| WO2004089933A1 (ja) | フルオロベンズアミド誘導体の新規結晶 |